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Abstract: Coenzyme Q10 (CoQ10) is a mitochondrial electron carrier and a powerful lipophilic 
antioxidant located in membranes and plasma lipoproteins. CoQ10 is endogenously synthesized 
and obtained from the diet, which has raised interest in its therapeutic potential against patholo-
gies related to mitochondrial dysfunction and enhanced oxidative stress. Novel formulations of 
solubilized CoQ10 and the stabilization of reduced CoQ10 (ubiquinol) have improved its bioavaila-
bility and efficacy. Synthetic analogues with increased solubility, such as idebenone, or accumu-
lated selectively in mitochondria, such as MitoQ, have also demonstrated promising properties. 
CoQ10 has shown beneficial effects in autoimmune diseases. Leukocytes from antiphospholipid 
syndrome (APS) patients exhibit an oxidative perturbation closely related to the prothrombotic 
status. In vivo ubiquinol supplementation in APS modulated the overexpression of inflammatory 
and thrombotic risk-markers. Mitochondrial abnormalities also contribute to immune dysregula-
tion and organ damage in systemic lupus erythematosus (SLE). Idebenone and MitoQ improved 
clinical and immunological features of lupus-like disease in mice. Clinical trials and experimental 
models have further demonstrated a therapeutic role for CoQ10 in Rheumatoid Arthritis, multiple 
sclerosis and type 1 diabetes. This review summarizes the effects of CoQ10 and its analogs in mod-
ulating processes involved in autoimmune disorders, highlighting the potential of these therapeu-
tic approaches for patients with immune-mediated diseases. 
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1. Introduction to Coenzyme Q and Coenzyme Q-Related Compounds 
1.1. Basic Principles 
Coenzyme Q (CoQ) is a prenylated para-benzoquinone that is found ubiquitously in 
aerobic organisms and is also present in all cells and tissues and in plasma lipoproteins, 
hence its denomination as ubiquinone [1,2]. CoQ isoforms are designated according to 
the number of isoprene units in the side chain with CoQ10 being the main isoform present 
in humans [3]. Those organs with high-energy requirements or metabolic activity such as 
the heart, kidney, liver and skeletal muscle contain the highest levels of CoQ [4]. The 
redox activity of CoQ resides in the quinone groups that can be reduced to the corre-
sponding hydroquinone to yield reduced CoQ, also known as ubiquinol, which can be 
oxidized to regenerate ubiquinone [5]. The majority of CoQ in tissues and plasma is 
found as ubiquinol, except for some organs such as brain and lungs, which appears to be 
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related to increased oxidative stress in these two tissues [4]. 
In the inner mitochondrial membrane CoQ mediates electron transport coupled to 
ATP synthesis [6,7]. Mitochondrial CoQ also participates in fatty acid β-oxidation, amino 
acid catabolism, pyrimidine biosynthesis, modulation of mitochondrial uncoupling pro-
teins (UCPs) sensitivity to purine nucleotides, and the regulation of the activity of the 
mitochondrial permeability transition pore [7]. At the plasma membrane, CoQ partici-
pates in a trans-plasma membrane redox system that has been related to the control of 
cell growth, the reoxidation of cellular nicotinamide adenine dinucleotide (NADH) un-
der conditions of mitochondrial dysfunction, and the regeneration of ascorbate in the 
extracellular space [8,9]. Another prominent function of CoQ (in its reduced form) is to 
provide antioxidant protection within the lipid phase of membranes and plasma lipo-
proteins, either directly or through the regeneration of α-tocopherol [3,7–9]. CoQ is also a 
potent stabilizer of membranes [10]. 
Whereas for some of these functions CoQ behaves as a vitamin-like molecule and its 
structure resembles that of vitamin K, it cannot be classified as such since it can be syn-
thesized endogenously [4]. In fact, CoQ is the only lipid-soluble antioxidant that can be 
synthesized by all aerobic organisms, from bacteria to humans [2,3]. Highest rates of CoQ 
biosynthesis are observed in metabolically active tissues such as the heart and immune 
system [11]. Mutations in several human CoQ10 biosynthesis genes result in primary 
CoQ10 deficiencies, but other genetic defects can also produce secondary 
CoQ10-deficiencies [12–14]. Endogenous biosynthesis can also be impaired under several 
pathological situations, and a deficiency in CoQ10 is also involved in cardiomyopathies 
and degenerative muscle and neuronal diseases [15–18]. The synthesis of CoQ10 may also 
be compromised by aging [19] and by the action of some pharmacological agents such as 
statins [20]. 
1.2. Pharmacokinetics of Coenzyme Q10 
CoQ10 is present in a normal diet, but its amount in dairy products is very low and it 
is poorly absorbed [11,21]. In the absence of an effective supplementation strategy, die-
tary CoQ10 is not sufficient to support its physiological functions and does not appear to 
contribute to the regulation of CoQ10 levels in tissues and in plasma, which, under normal 
circumstances, are determined by the rate of its endogenous biosynthesis taking place in 
all tissues [22]. Augmentation of CoQ10 levels by dietary supplementation may amelio-
rate the deleterious consequences of CoQ10 deficiencies, and CoQ10 is also currently a 
popular over-the-counter dietary supplement. However, orally administered CoQ10 is 
also poorly absorbed. Although the absorption of CoQ10 can be enhanced by the presence 
of lipids in the diet, only a minor proportion of the CoQ10 that is ingested is effectively 
absorbed [4]. In consequence, the percentage of supplemental CoQ10 that is effectively 
incorporated decreases as the supplement increases, and those doses that exceed that 
capacity for absorption have a minimal effect on efficacy [23]. While the use of high doses 
of CoQ10 appears thus unnecessary because it increases the cost of the treatment without 
significant benefits, there is an excellent safety record for CoQ10 [24–27]. Moreover, ex-
ogenous CoQ10 does not affect its endogenous biosynthesis, nor does it accumulate into 
plasma or tissues once supplementation has ceased [15]. 
1.3. Coenzyme Q10 Formulations with Enhanced Bioavailability and Coenzyme Q10-Related 
Compounds with Therapeutic Interest in Autoimmune Diseases 
The poor bioavailability of CoQ10 has prompted the search of formulations that im-
prove its absorption and delivery to the target compartments. The uptake of CoQ10 is 
further compromised by its instability to light and thermolability [11,28]. Efforts to en-
hance CoQ10 bioavailability have mainly been directed towards the reduction in particle 
size and the increase of water solubility/dispersibility using complexation, solubilization, 
or reduction [29]. Very promising results using modified-release preparations have also 
been reported [30]. The different procedures to increase the bioavailability and stability of 
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CoQ10 in formulations have been revised recently [11,31], and include liposomes, li-
pid-free nano-formulation, water-soluble CoQ10 complexes with β-cyclodextrin, 
self-nanoemulsifying CoQ10, CoQ10-loaded oleo-gels, and CoQ10 micellization with cas-
pofungin [31]. In general, the relative bioavailability of CoQ10 is strongly dependent on 
the delivery system, with the order of decreasing bioavailability being: nanoparticulated, 
solubilized, oil-emulsioned and powder [12]. Absorption of CoQ10 is also substantially 
improved when provided in the form of ubiquinol [25–32] 
Another attempt to overcome the low bioavailability of CoQ10 has been represented 
by the development of short-chain analogues that can be easily delivered to those sites 
where improvement of CoQ10 function is needed. These analogues include molecules 
such as MitoQ and the SkQ series that accumulate specifically in the mitochondria driven 
by the electrochemical potential, as well as molecules such as idebenone and EPI-743 
which are not targeted to the mitochondria but shuttle between this organelle and the 
cytosol for the regeneration of their active hydro-quinones [12,33]. These analogues have 
already been tested in clinical assays with promising results for the treatment of several 
diseases associated with the impairment of mitochondrial function and, among them, 
idebenone and MitoQ have been tested in the treatment of autoimmune diseases (see 
below). 
2. Relevance of Oxidative Stress and Mitochondrial Dysfunction in the Physio-
pathology of Autoimmune Disorders 
2.1. Oxidative Stress, Mitochondrial Dysfunction and Disease 
Molecular oxygen is the driving force behind oxidative phosphorylation. Through 
this process, mitochondria use multi-subunit enzyme complexes to oxidize nutrients and 
use the released energy to form adenosine triphosphate (ATP). This absolutely vital 
function is, however, inevitably connected to the creation of highly reactive and toxic side 
products, the reactive oxygen species (ROS) [34]. 
It has been demonstrated that ROS are not only by-products but can also act as 
secondary messengers. Thus, mitochondrial ROS are not simply the price we pay for 
respiration, but also essential for regulating mitochondrial function and physiology. Be-
sides, ROS are not only produced during oxidative phosphorylation, but also, and in 
even higher amounts, by NADPH oxidase complexes (NOX). The best described and 
most potent of these complexes is NOX2, which is predominantly expressed in phago-
cytic cells such as neutrophils, monocytes and macrophages, or dendritic cells (DC), and 
is the dominant ROS-generating complex in mammals [35]. 
Both reactive oxygen and nitrogen species (RNS), mainly represented by nitric oxide 
(·NO), superoxide anion radical (·O2−), peroxy-nitrite anion (ONOO−), hydroxyl (·OH), 
lipo-peroxide (LOO·), hydrogen peroxide (H2O2), and hypochlorous acid (HClO), are 
highly reactive molecules generated both during physiological cellular processes and 
under several pathological conditions [36–39]. In addition to the presence of increased 
amounts of ROS/RNS in conditions of oxidative stress, antioxidants can behave as regu-
latory players, as they are capable of scavenging ROS/RNS, thus inhibiting the cell oxi-
dation [40]. Antioxidants encompass enzymatic and nonenzymatic systems. The enzyme 
system primarily includes catalase (CAT), superoxide dismutase (SOD), glutathione pe-
roxidase (GPx), glutathione reductase (GR) and thioredoxin reductase. The nonenzy-
matic antioxidant system contains some vitamins [41]. 
The main function of mitochondria is the production of ATP through oxidative 
phosphorylation. In addition, it is involved in the generation and detoxification of ROS, 
apoptosis, synthesis and catabolism of metabolites, regulation of mitochondrial and cy-
toplasmic matrix calcium, and transport of organelles themselves to the correct location 
inside the cells. Any anomaly in these processes can be named mitochondrial dysfunction 
[42]. 
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There are different ways to assess mitochondrial dysfunction depending on whether 
function is determined in isolated mitochondria or in intact cells. The most simple and 
useful test to identify energetic dysfunction in isolated mitochondria is to measure mi-
tochondrial respiratory control. The measurement of the protonmotive force (pmf) and 
the identification of respiration rate under different conditions and states can clarify the 
mechanism. However, the best way to obtain mechanical insights is to titrate both respi-
ration rate and pmf at the same time, and draw dynamic diagrams of differential oxida-
tive phosphorylation [43]. 
In intact cells, the analysis of cell respiratory control is the most useful test to evalu-
ate mitochondrial function. That testing yields information that allows a quick, simple 
and full assessment of the bioenergetic status of the cells: how fast they are turning over 
ATP, how well-coupled their mitochondria are, and how much spare respiratory capacity 
they have available to deal with energetic demands. The determination of the mito-
chondrial membrane potential (ΔΨm) can also be very helpful. Mitochondrial membrane 
potential is a key marker of mitochondrial activity, as it reveals the electron transport 
process and oxidative phosphorylation, which is the energetic force for ATP production. 
Thus, the ΔΨm is a major indicator of cell health or damage [44]. 
Ultimately, mitochondrial dysfunction can be assessed by analyzing its ‘dynamics’. 
Mitochondria experience coordinated cycles of fission and fusion, commonly known as 
‘mitochondrial dynamics’ to preserve their shape, size and distribution. Mitochondrial 
fusion leads to tubular, elongated, and interconnected mitochondrial nets. This process is 
under the control of the fusion proteins mitofusin (Mfn-1, Mfn-2), and optic atrophy 
protein 1. On the contrary, mitochondrial fission generates divided and discontinuous 
mitochondria in a process coordinated by the mitochondrial fission proteins dy-
namin-related protein 1 (Drp1) and the human fission protein 1 (hFis1) [45]. 
Functionally, mitochondrial fission and fusion may modify the consumption of ox-
ygen, mitochondrial respiration and the mitochondrial membrane potential. Besides, 
mitochondrial dynamics are crucial for a variety of biological processes such as apopto-
sis, respiration, mitosis, and development. Moreover, numerous studies have reported 
abnormal mitochondrial morphology, impacting on a broad range of pathological pro-
cesses and associated with a number of human diseases [46]. Finally, mitochondrial bio-
genesis, the complex cellular process of new mitochondria generation, has a key role in 
boosting mitochondrial function. Together with fission/fusion, biogenesis is vital for the 
homeostasis of the mitochondria, for the exclusion and elimination of damaged mito-
chondria and, fundamentally, for the regeneration of the mitochondrial network in the 
cells [47]. 
Jointly, oxidative stress and concomitant mitochondrial dysfunction damage both, 
molecules and cellular structures, thus altering the correct function of organs and sys-
tems, promoting chronic tissue inflammation, dyslipidemia and atherosclerosis [48,49]. 
In addition, oxidative stress may promote immunomodulation, which leads autoimmune 
disease development [50,51] (Figure 1). Likewise, long-term treatments may promote 
changes in systemic oxidative stress, thereby affecting the development of these diseases. 
2.2. NETosis as an Essential Link between Oxidative Stress and Autoimmunity 
Neutrophils, key players in the immune system, are known for their antimicrobial 
function, being the key effectors against infections. In addition to the production of ROS 
and the release of microbicidal molecules, it has been described that neutrophils have an 
antimicrobial activity called NETosis. NETosis is a process of cell death, distinct from 
necrosis and apoptosis, in which, sequentially, a dissolution of inner membranes fol-
lowed by chromatin decondensation occurs, along with their joint release into the extra-
cellular space [52,53]. These webs of chromatin fibers, called neutrophil extracellular 
traps (NETs), contain histones, antimicrobial peptides, and oxidant-generating enzymes 
such as myeloperoxidase (MPO), neutrophil elastase, NOX and NO synthase (NOS). 
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Figure 1. Pathogenic role of oxidative stress and mitochondrial dysfunction in Systemic Autoimmune Diseases. Enhanced 
oxidative status and mitochondrial dysfunction are hallmarks of Systemic Autoimmune Diseases. These processes pro-
mote the alteration of key physiological functions such as the ability to repair vascular tissue, the control of apoptosis and 
the development of NETosis. The impaired functions are directly associated with tissue and organ damage in the long 
term. The dysregulation of the immune system leads to the loss of tolerance which drives autoantibody production, in-
flammation and the consequent increase of the disease activity. Furthermore, the chronic establishment of an altered ox-
idative status can trigger the development of cardiovascular comorbidities such as atherosclerosis and endothelial dys-
function. ROS, Reactive oxygen species. 
The generation of NETs requires the production of ROS [52,54–56]. Thus, several 
mechanisms by which ROS induces NET formation have been described: (i) they lead the 
release of neutrophil elastase by increasing the permeability of the membrane, which in 
turn degrades the core histones and the linker histone H1, driving chromatin deconden-
sation; this process is further enhanced by MPO [57]. (ii) ROS promotes the morpholog-
ical changes of neutrophils occurred during NETosis [58] and (iii) ROS can induce au-
tophagy, leading to cell membrane dissolution. 
Originally, NETosis was considered just as a mechanism of immune response to in-
fections, but numerous studies have demonstrated that these structures are key factors in 
many pathologic states, because they can produce tissue damage, atherosclerosis and 
thrombosis [59]. In addition, NETs are closely linked to autoimmunity so that several 
proteins in these structures, including MPO and dsDNA, may also serve as potent au-
toantigens [60,61]. Given the close relationship between oxidative stress and NETosis, 
therapies aiming at the regulation of oxidative stress also involve the reduction of  
NETosis, thus helping to improve the clinical status of patients with chronic and auto-
immune pathologies. 
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2.3. Oxidative Stress in Antiphospholipid Syndrome 
Antiphospholipid Syndrome (APS) is a systemic autoimmune disease characterized 
by pregnancy morbidities and/or a hypercoagulable state of the venous or the arterial 
vasculature, associated with the persistence of antiphospholipid antibodies (aPLs), com-
prising anti-beta2-glycoprotein I (anti-ß2GPI), anti-cardiolipin antibodies (aCL), and 
Lupus anticoagulant (LA). These patients mainly suffer vascular damage, including 
thrombosis, atherosclerosis, myocardial infarction or stroke [62,63]. 
Antiphospholipid antibodies have been demonstrated to induce an increased ex-
pression of numerous molecules involved in thrombosis development, such as pro-
thrombotic molecules (i.e., tissue factor, the main inductor of coagulation in vivo), in-
flammatory mediators, cell-adhesion receptors, NETosis, and numerous intracellular 
signaling molecules. Besides, oxidative stress has been shown to be involved in the 
pathophysiology of APS, so that an enlarged oxidative status in plasma, demonstrated by 
high levels of prostaglandin 2 and 8-isoprostane, has been proven in APS patients, par-
ticularly those showing triple positivity for aPLs [64]. 
Autoantibody production has been associated with plasma oxidation, endothelial 
activation, and vascular disease in APS patients. aPLs provoke superoxide and NO 
production, which results in increased levels of plasma peroxy-nitrites [65]. In addition, 
titers of aCL antibodies correlated with plasma levels of F2-isoprostanes, biomarkers of in 
vivo lipid peroxidation [66,67]. Lower activity of para-oxonase, an antioxidant enzyme 
associated to high-density lipoproteins (HDL) that prevents the oxidation of low-density 
lipoproteins, has also been linked to the presence of arterial anomalies. In addition, HDL 
shows antioxidant and anti-inflammatory properties, and reduces the bioavailability of 
NO [68]. 
Antiphospholipid antibodies are also responsible for the endothelial dysfunction 
that characterize these patients, through the activation of transcription factors such as the 
nuclear factor kB and, consequently, of the induced NO synthase (iNOS). This oxidative 
status, in concert with the autoimmune vascular inflammation of APS patients, also 
promotes the formation of the oxLDL/B2GPI complexes, which further contribute to 
vascular injury and atherothrombosis development [69]. 
At molecular level, in a previous study [70] we demonstrated increased production 
of ROS by circulating leukocytes from APS patients (i.e., monocytes and neutrophils), 
associated with altered mitochondrial membrane potential, which was related to the au-
toimmune profile and the pro-aterothrombotic status of these patients. Moreover, in vitro 
studies showed that aPL-IgG promoted a redox-sensitive signaling pathway in mono-
cytes that regulated their prothrombotic profile. Parallel studies showed that aPLs pro-
moted the generation of superoxide in plasmacytoid dendritic cells and monocytes, 
which in turn upregulated the expression of TLRs 7 and 8 [71]. Overall, these data have 
established the key role of autoimmunity in the oxidative status present in APS patients, 
which leads to the development of cardiovascular disease. 
More recent studies have suggested a relevant role for NETosis in the prothrombotic 
status of APS patients. Thus, high levels of NETs were observed in the plasma of these 
patients, further linked to the occurrence of thrombotic events. Moreover, it has been 
shown that aPLs activate neutrophils to release NETs, thus predisposing to thrombosis 
[72,73]. 
In recent years, a number of works have identified several genes involved in 
thrombosis, inflammation and endothelial dysfunction in APS patients (i.e., TF, PAR1, 
PAR2, VEGF, Flt1, TLR2, TLR4, IL8, etc.). These genes are overexpressed in immune and 
vascular cells (platelets, monocytes, neutrophils, and endothelial cells) and induce 
thrombin generation and enlarged procoagulant activity [74–79]. Microarray studies car-
ried out by our group have also identified the altered expression in APS monocytes of 
several genes involved in mitochondrial biogenesis and function, antioxidant defense, 
and oxidative stress, all of them linked to thrombosis development [80]. Mechanistic 
studies further demonstrated that aPLs modulated in these cells the expression of a 
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number of genes involved in this pro-thrombotic status, such as SLC25A27, IL-11RA, 
CCL2, IFIT1, PPARγ, and ARHGEF5. 
More recently, the occurrence of a fine post-transcriptional regulation of gene ex-
pression has been demonstrated in autoimmune diseases. Among them, microRNAs are 
non-protein coding small RNAs which are ubiquitously expressed and deregulated in 
most pathologies, that regulate almost every cellular process [81]. Our group has char-
acterized several microRNAs in monocytes from APS and SLE patients [82], further re-
lated to the cardiovascular feature of these pathologies. Among them, the reduced ex-
pression of miR-125a, miR-155 and miR-146a were linked to the cellular levels of perox-
ides, the altered mitochondrial membrane potential (ΔΨm) and the augmented activity 
of mitochondrial SOD. Hence, transfection of monocytes with miR-125a mimic provoked 
a downregulation of peroxides production, suggesting that the upregulation of these 
microRNAs might promote the loss of mitochondrial integrity and function, thus estab-
lishing a pro-oxidative status in APS patients. 
2.4. Oxidative Stress in Systemic Lupus Erythematosus 
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by a mul-
tisystemic inflammatory status associated with the presence of antibodies in cytoplasmic and 
nuclear antigens, with a relapsing and remitting course. The etiology of this disease involves 
genetic, immune, hormonal, and environmental dysfunctions, although molecular mecha-
nisms explaining this altered autoimmune response are still undetermined. 
Oxidative stress plays a relevant role in the pathogenesis of SLE, through the in-
duction of inflammation, apoptosis and breaking of immune tolerance [83,84]. Thus, the 
interaction of macromolecules generated by apoptosis with ROS generates neo-epitopes 
that expand antibody flares, which contribute to tissue damage in SLE patients [85,86]. 
NETosis is also augmented in SLE, which, along with the reduced capacity to degrade 
NETs by nucleases, increases tissue damage [87]. Moreover, enzymes engaged in the NETs, 
such as MPO and NOX, have been shown to oxidize HDL. Hence, these lipoprotein parti-
cles acquire a pro-atherogenic form that impairs the cholesterol efflux capacity, leading to 
lipoprotein oxidation and increasing the cardiovascular risk in SLE [88]. 
The inflammatory burden of SLE, along with the elevated production of ROS and 
the reduced antioxidant capacity [89] may further contribute to the worsening of the 
disease and the occurrence of cardiovascular events. Accordingly, in biological fluids 
increased levels of oxidized biomolecules have been demonstrated (i.e., MDA 
(malondialdehyde)-modified proteins, anti-SOD and anti-catalase antibodies, and albu-
min modified by HNE (4- hydroxy 2-nonenal)), which correlate with disease activity and 
organ damage [90,91]. In addition, levels of F2-isoprostane (8-iso-PGF2), increased in 
urine from SLE patients, are also associated with disease activity [92]. Many independent 
studies have equally identified elevated levels of MDA, F2-Isoprostane, and NO, along 
with diminished levels of GSH in patients with lupus nephritis [93–96]. 
Some years ago, Lopez et al. [97] proposed that elevated levels of oxidized 
low-density lipoproteins (oxLDL) along with high titers of autoantibodies might act as 
risk factors for CVD in SLE patients. Thereafter, in a cohort of 40 SLE patients, Yailmaz et 
al. [98] demonstrated the occurrence of subclinical coronary microvascular dysfunction in 
SLE patients associated with inflammation (increased CRP levels) and impaired total an-
tioxidant capacity of plasma. 
Our group also reported altered myeloid cell activity in SLE patients, involving cell 
activation, inflammation and enlarged oxidative status in monocytes and neutrophils. 
Thus, altered expression of cell surface receptors, cytokines/chemokines, regulators of 
endothelial cells and molecules related to oxidative stress were found closely interrelated 
and associated with the development of atherosclerosis and CVD in these patients [99]. 
Mitochondrial dysfunction was also demonstrated in these patients, further linked to 
their prothrombotic and inflammatory status, as indicated by correlations with inflam-
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matory mediators and by the association between the percentage of monocytes showing 
depolarized mitochondria and the occurrence of thrombotic events. 
Overall, the noxious effects of ROS in SLE cause several effects: (i) shift of intracel-
lular redox condition, i.e., decreased GSH/GSSH ratio, (ii) leukocyte mitochondrial dys-
function; (iii) oxidative modification of lipids, proteins and DNA, identified by increased 
levels of various biomarkers in serum and leukocytes, such as oxygen radicals (i.e., per-
oxides and hydroxyl radicals), oxidative-DNA damage markers (i.e., 8-oxodG), bi-
oproducts of protein oxidation (i.e., carbonylated proteins and 3-nitrotyrosine) and bi-
oproducts of lipid peroxidation (i.e., malondialdehyde, isoprostanes); (iv) activation of 
oxidative stress and gene mutations associated with antioxidant enzymes. All these al-
terations ultimately drive the evolution of the disease, the organ damage and the occur-
rence of comorbidities such as atherothrombosis. 
2.5. Oxidative Stress in Rheumatoid Arthritis 
Rheumatoid Arthritis (RA) is a systemic autoimmune disease characterized by 
chronic joint inflammation, which fosters cartilage and bone damage and ultimately 
leads to systemic involvement. Besides, RA may affect several organs outside the joints, 
including the lung, skin and cardiovascular system [100]. 
RA development involves numerous pathogenic mechanisms and clinical manifes-
tations, even among individuals with same diagnosis and/or throughout different stages 
of the disease, which support its complexity and the participation of multiple factors in 
both the trigger and the evolution of the disease. 
Oxidative stress is a key contributor to the pathogenesis of RA. ROS, overproduced 
in joints and circulating myeloid cells, damage cellular structures and molecules such as 
lipids, proteins, carbohydrates and DNA [101]. Accordingly, RA patients display in-
creased levels of oxidation bioproducts, including lipo-peroxides (LPO), carbonylated 
proteins, nitro-tyrosine, and oxidized DNA [102]. 
Inflammation is the major pathologic mechanism of RA. Correspondingly, a close 
link between redox reaction producing oxidative stress and the pathophysiology of in-
flammation in this autoimmune disease has been demonstrated [103,104]. Thus, ROS can 
modify the signaling of nuclear factor κB (NF-κB), the transcription factor regulating 
most immune and inflammatory processes [105]. ROS can induce the translocation of 
NF-κB to the nucleus, while the overexpression of the antioxidant enzyme superoxide 
dismutase 2 (SOD2) inhibits this process [106,107]. Likewise, ROS induce other tran-
scription factors related to cell differentiation, vascularization and proliferation, such as 
inducible hypoxia factor (HIF-1), activator protein 1 (AP-1) and gamma-activated perox-
isome proliferator receptor (PPARγ) [108–110]. It has been further shown that mito-
chondrial ROS promote the production of key inflammatory cytokines (IL1β, IL-6, and 
TNFα) [111]. 
In turn, the inflammation process also induces oxidative stress, so that neutrophils 
can generate ROS by the NADPH oxidase enzyme pathway [112,113]. Therefore, through 
interactions among inflammation and oxidative stress, the effects of both pathogenic 
mechanisms are heightened. 
Regarding the damage promoted by ROS in key cells involved in the pathophysi-
ology of RA, it has been shown that ROS induce the death of chondrocytes, along with a 
high inflammatory injury, both at articular and systemic levels. Moreover, positive cor-
relations between ROS and disease activity score (DAS28) have been demonstrated, 
supporting the hypothesis that ROS can be a predictive biomarker of the inflammatory 
status of RA patients [101]. Similarly, a reduced antioxidant status, also identified in 
these patients, is associated with a higher inflammatory damage. 
Some post-translational protein modifications also occur under pro-oxidative con-
ditions, thus generating neoepitopes identified as ‘non-self’ by the immune system that 
promote the formation of new autoantibodies, which, in turn, lengthen the pathologic 
process [114]. Likewise, we previously showed that anti-citrullinated protein antibodies 
Antioxidants 2021, 10, 600 9 of 25 
 
(ACPAs, the most specific autoantibodies of RA) induce a pro-oxidative status in neu-
trophils and monocytes, in parallel to a pro-inflammatory profile in lymphocytes and 
monocytes [115]. Thus, ROS can be considered as biomarkers for the prediction of the 
inflammation and the disease activity status of RA patients. 
2.6. Oxidative Stress in Type I Diabetes 
Type 1 diabetes (T1D) is a chronic autoimmune disease mediated by T cells, which 
develops mainly in children and adolescents. It gradually destroys the beta cells of 
Langerhans islets, resulting in insufficient insulin production. The reduced circulating 
insulin levels result in reduced glucose uptake by the tissues, leading to intracellular 
hypoglycemia and extracellular hyperglycemia. Subsequently, chronic hyperglycemia 
can cause macrovascular and microvascular complications such as cardiovascular dis-
ease (including stroke, atherosclerosis, and myocardial infarction), neuropathy, 
nephropathy, and retinopathy [116]. 
Several factors (genetic, immunological and/or environmental) are involved in the β 
cell death mechanisms that lead to insulin deficiency. In addition, oxidative stress further 
contributes to both the worsening of the disease and inflammatory complications 
[117,118]. 
A considerable body of evidence supports the concept that T-cell mediated infiltra-
tion of the pancreas leads to generation of ROS, along with the production of proin-
flammatory cytokines, mainly TNFα, IL-1β and IFNγ. Thus, locally produced ROS are 
involved in the effector mechanisms of beta cell destruction in vitro and, correspond-
ingly, T cells and macrophages’ secreted cytokines such as IFNγ, IL-1β and TNFα, induce 
the production of ROS by B-lymphocytes [119], leading to a chronic inflammatory status. 
Concomitantly, the demonstrated low serum antioxidant status in T1D patients, 
identified by reduced urate, and vitamin C total antioxidant capacity [120,121] promote 
an oxidative modification of proteins and lipids [122]. Moreover, the mitochondria of 
β-cells have very low levels of antioxidant enzyme activity of catalase, glutathione pe-
roxidase and superoxide dismutase [123,124] which make β-cells prone to disruption by 
oxidative stress and, in genetically predisposed individuals, to develop targets for a 
subsequent cytokine-mediated autoimmune attack. 
There are also indications that oxidative stress is involved in other aspects of auto-
immune diabetes including macrophage-mediated clearance of apoptotic cells and com-
plications that develop in the vasculature of diabetic patients [125]. Likewise, vascular 
complications are, at least partially, dependent on hyperglycemia, which promote tissue 
damage by three main mechanisms: (i) increased polyol activity, which causes accumu-
lation of fructose and sorbitol; (ii) increased generation of advanced glycation end 
products (AGEs); and (iii) protein kinase C activation and enlarged hexosamine pathway 
flux. These pathways, along with hyperglycemia induced by mitochondrial dysfunction 
and endoplasmic reticulum stress, induce ROS accumulation which, in turn, provokes 
cell damage and the worsening of the disease status. Moreover, ROS damage proteins, 
lipids and DNA and regulate several cellular signaling pathways, i.e., mitogen activated 
protein kinases and redox-sensitive transcription factors, that cause alteration in protein 
expression, leading to oxidative modifications that have a relevant role in vascular dis-
eases’ development [126]. 
Overall, helpful therapies for T1D patients should bring not just protection from 
ROS of the β-cells, but also prevention of autoimmune attack mediated by ROS, which 
may be achieved by two main processes: (a) preventing NF-κB activation, thus reducing 
inflammation and the initiation of the adaptive immune response, and (b) reducing hy-
perglycemia that leads to disease progression and vascular involvement. 
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2.7. Oxidative Stress in Multiple Sclerosis 
The central nervous system (CNS) is especially susceptible to the damage of oxida-
tive stress due to its elevated oxygen requirement and to its high levels of lipids easily 
suffering peroxidation [127,128]. Neurodegenerative diseases, which are characterized by 
the degeneration and death of neurons that lead motor and cognitive dysfunction, are 
closely related to oxidative stress [129,130]. Specifically, astrocytes and microglia espe-
cially contribute to neurodegeneration [131,132]. Yet, it remains unclear whether the high 
levels of ROS/RNS identified in the brain of patients with neurodegenerative diseases are 
the cause or the consequence of that degenerative process. 
Multiple Sclerosis (MS), the most frequent chronic inflammatory disease of the CNS, 
is characterized by completely or partially reversible episodes of worsening of the neu-
rological functions, lasting for days or even weeks. MS is branded by a destruction of 
myelin, glial reaction, and chronic inflammation. It is still not known if the cause of tissue 
damage in MS is intrinsic or extrinsic to the CNS. In MS, several factors, such as genetic, 
environmental, cultural, socioeconomic, personal lifestyle, and/or aging, lead to the for-
mation of a causative complex and ultimately converge into parallel pathognomonic 
clinical pictures. Nonetheless, a number of studies have demonstrated a key role for 
adaptive immunity in the pathogenesis of MS [133]. 
Inflammatory and demyelinating attacks are unique manifestations in MS, but dif-
ferent patho-mechanisms manage the clinical courses in each MS subtype. Among them, 
disturbance of redox metabolism plays a key role in the pathogenesis of MS. However, it 
is still unknown if the events of inflammation and neurodegeneration that characterize 
this disease are the cause, a complementary process, or a resultant event of ROS damage 
[134,135]. 
Proteomics analyses in serum have shown that several proteins are up-regulated in 
relapse-remitting MS (RRMS) patients, such as apolipoprotein E, clusterin, ceruloplasmin 
and complement C3. In these patients it was also demonstrated that vitamin D-binding 
protein had a trend to oxidation, along with increased oxidation of apolipoprotein A-IV, 
leading the progression from remission to relapse of MS [136]. 
Cerebrospinal fluid (CSF) of patients in the remission stage of RRMS also displays 
increased uric acid levels (a product of purine oxidation), abridged antioxidants, and 
augmented synthesis intrathecal of IgG [137]. Several observations have further demon-
strated the presence of redox metabolism disturbance and involvement of inflammation 
in RRMS. Finally, lower concentrations of GSH in the frontoparietal region of patients 
with primary progressive MS and secondary progressive MS than in RRMS have been 
observed [138]. 
Taken together, oxidative stress in CNS is closely related to neurodegeneration in 
patients with progressive types of MS. Thus, the quantification of various redox compo-
nents, including oxidative and antioxidative enzymes, along with the products of deg-
radation during disease progression and degradation products during its progression, 
might accelerate the development of the most suitable personalized treatment plans for 
MS patients [139]. 
3. CoQ10 as a Potential Therapeutic Tool in Systemic Autoimmune Diseases 
3.1. Antiphospholipid Syndrome and Systemic Lupus Erythematosus 
Precedent studies by our group identified the key role of oxidative stress and mito-
chondrial dysfunction in plasma and leukocytes from APS patients on the establishment of 
their pro-atherothrombotic status. We further showed their stimulation by aPLs, and the in-
hibitory effects of in vitro treatment with CoQ10 on these processes [51,70]. Thereafter, 
through the implementation of a prospective, randomized, double-masked, place-
bo-controlled study (Clinical Trials.gov: NCT02218476), we evaluated the in vivo effects of 
ubiquinol supplementation to the standard therapy of APS patients on parameters related to 
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thrombosis and inflammation. In this clinical trial, thirty-six patients were randomized to 
receive either, ubiquinol (200 mg/day) or placebo for 1 month [140] (Figure 2 and Table 1).  
 
Figure 2. Clinical trial: Ubiquinol supplementation in antiphospholipid (APS) Patients. A randomized, crossover, place-
bo-controlled trial was carried out in 36 APS patients to analyze the beneficial effects of supplementation with Ubiquinol 
(200 mg/day) for one month. Changes in several parameters related to inflammation, oxidative stress, mitochondrial 
function, atherosclerosis, and NETosis, along with regulatory microRNAs, were assessed. The results demonstrated the 
high potential of Ubiquinol to modulate markers associated with thrombosis and cardiovascular disease in APS patients, 
highlighting its role as a safe adjunct to standard therapies in this autoimmune disorder. 
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Firstly, a direct anticoagulant effect of ubiquinol administration for one month was 
established, as demonstrated by the significant inhibition in APS monocytes of the ex-
pression and activity of Tissue Factor (TF), previously shown to be directly involved in 
the pathogenesis of thrombotic complications in APS patients. Besides, after ubiquinol 
treatment, plasma and cellular levels of several markers related to endothelial function, 
cell surface receptors, cytokines and chemokines were found jointly reversed. Likewise, a 
higher percentage of low-potential mitochondria in monocytes, accompanied by a lower 
ROS production, and the upregulation of genes related to mitochondrial biogenesis was 
observed in response to in vivo ubiquinol treatment. In parallel, a significant improve-
ment of the microvascular function in patients with APS, with a significant increase in the 
peak flow and the area of reactive hyperemia after temporary occlusion of blood flow, 
was also demonstrated. Accordingly, levels of cell adhesion molecules, such as vascular 
cell adhesion molecule 1, were found diminished in APS patients’ plasma. A direct effect 
of ubiquinol in inhibiting NETosis was further demonstrated, thus suggesting a direct 
link between both processes. Thus, our data point at ubiquinol as a beneficial antioxidant 
compound that further prevents toxic side effects of NETs in inflammation and throm-
bosis in patients with APS. 
Lastly, our results demonstrated, for the first time, an altered expression of various 
microRNAs by the effect of ubiquinol, most of them having as potential targets several 
factors involved in inflammation and thrombosis. Therefore, the increased levels of these 
microRNAs after ubiquinol supplementation might be associated with a reduction in the 
prothrombotic profile of APS patients. Accordingly, the integrated analysis of validated 
microRNAs and the altered genes identified by a polymerase chain reaction array of 
atherosclerosis demonstrated the presence of a complex network related to CVD, on 
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which several ubiquinol-upregulated microRNAs seem to simultaneously control the 
expression of various ubiquinol-downregulated genes. 
In summary, our results have supported the short-term impact of ubiquinol sup-
plementation in the reduced expression of several markers related to inflammation and 
thrombosis in APS patients. Because of the notable absence of clinically significant side 
effects and its potential therapeutic benefits, this study suggested that ubiquinol might 
act as a safe adjunct to standard therapies in patients with APS. To the best of our 
knowledge, this is the only study developed up to now analyzing the beneficial effects of 
CoQ10 supplementation in the treatment of this autoimmune disorder. Nevertheless, new 
studies in larger cohorts are required to support their use in daily clinical practice. 
In the setting of SLE, a very recent study has evaluated the potential therapeutic 
benefits of the CoQ10 analog Idebenone in two murine models of lupus [141]. In this 
study, MRL/lpr mice were treated orally with Idebenone at 2 different doses (1 gm/kg or 
1.5 gm/kg idebenone-containing diet) for eight weeks. Activity, immunologic, clinical, 
and metabolic parameters were evaluated at peak disease and compared to those in un-
treated mice. These results were further confirmed using the lupus-prone NZM2328 
mouse model. Interestingly, Idebenone-treated mice showed a significant decrease in 
mortality rate after eight weeks of therapy. Moreover, the treatment mitigated some 
disease features, such as glomerular inflammation and fibrosis, and improved renal 
function in association with decreased IL-17A and IL-18 renal expression. Splenic proin-
flammatory cytokines and inflammasome-related genes were also decreased in Idebe-
none treated mice, without any drug toxicity. Furthermore, Idebenone downregulated 
NETs formation in neutrophils and inhibited neutrophil extracellular trap formation in 
neutrophils from lupus-prone mice, while improving mitochondrial metabolism and 
ATP production, ameliorating endothelium-dependent vasorelaxation and reducing li-
pid peroxidation. Finally, Idebenone-treated NZM2328 mice showed a better renal func-
tion and a reduced systemic inflammation, involving reduced expression of interferon 
and inflammasome-related genes. In summary, the results of this study have indicated 
that Idebenone improves immune dysregulation, organ damage, vasculopathy, and mi-
tochondrial function in murine SLE through pleiotropic effects on the immune com-
partment, immunometabolism, and tissue damage. 
In a parallel study, Fortner et al. [142] investigated the therapeutic potential of the 
mitochondria-targeted antioxidant MitoQ on lupus disease manifestations in MRL-lpr 
mice. In this study, lupus-prone MRL-lpr mice were treated with MitoQ (200 µM) for 
eleven weeks. After therapy, reduced NETosis and ROS production were observed, along 
with downregulated serum levels of IFN and reduced immune complex formation in 
kidneys. 
These overall finding suggest that agents modulating mitochondrial ROS and oxi-
dative stress, administered as adjuvant therapy to traditional immunosuppressive ther-
apy, might have a therapeutic role in the treatment of SLE (Figure 3 and Table 1). 
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Figure 3. Beneficial effects of CoQ10 in Systemic Autoimmune Diseases. The therapeutic potential of CoQ10 in Systemic 
Autoimmune Diseases has been widely investigated. Thus, numerous studies comprising in vitro analysis, preclinical 
murine models and randomized controlled clinical trials have demonstrated the capacity of CoQ10 to improve the main 
clinical features of each disease, through both immunomodulatory and antioxidant effects. DAS28, Disease Activity Score 
using 28 joint counts; EDSS, Expanded disability status scale; FSS, Fatigue severity scale; BDI, Beck’s depression inven-
tory; VAS, Visual analogue scale for pain. 
3.2. Rheumatoid Arthritis 
Several preclinical studies in animal models of RA along with clinical trials in pa-
tients have demonstrated the beneficial effects of CoQ10 in the reduction of the oxidative 
and inflammatory status as well as clinical features that characterize this systemic au-
toimmune disease. 
Jhun J. et al. showed that daily oral administration of 20 mg/kg CoQ10 to zymo-
san-induced arthritis (ZIA) for seven weeks significantly decreased the severity of RA 
[143]. Cartilage damage as well as the infiltration of inflammatory cells was notably 
lower in CoQ10 treated mice in relation to the vehicle. Immunohistochemical analysis of 
synovial tissues identified a reduction in the levels of both pro-inflammatory mediators 
such as TNF, IL1, IL17, IL21 and VEGF, and oxidative stress markers including iNOS and 
nitro-tyrosine. In addition, CoQ10 reduced osteoclast genesis markers such as RANK and 
RANK-L in joint tissues which was in line with the decrease of bone erosion and cartilage 
damage noticed in the mouse model of RA. CoQ10 also exhibited immunomodulatory 
effects on B and T-cells. Markers of germinal center B cells such as CD220, CD138 and 
GL-7 were reduced along with the levels of total IgG, IgG1 and IgG2a in CoQ10 treated 
mice. Moreover, markers of T follicular helper cells were also decreased including PD-1, 
ICOS and GL-7. In spleen tissues, CoQ10 promoted the downregulation of Th17-cells, the 
inhibition of pSTAT-3 in these cells, and the up-regulation of Foxp3-expressing Treg cells. 
The immunomodulatory effects of CoQ10 have also been shown in other mouse 
models of RA like collagen-induced arthritis (CIA). In a very recent study, the oral ad-
ministration of CoQ10 encoded in liposome/gold hybrid nanoparticles (LGNP CoQ10) for 
10 weeks showed the reduction of the pathology scores of RA including bone damage, 
cartilage damage and immune cells infiltration [144]. The levels of pro-inflammatory 
cytokines such as IL6, TNF, IL17 and IL1 were reduced in the joints of CoQ10-treated 
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mice. Similar effects related to the reduction of Th17 and P-STAT-3 cells as well as osteo-
clast genesis markers were also identified in this animal model. 
In another study using CIA mice, Lee et al. demonstrated that the combination of 
CoQ10 with other dietary supplements such as Zinc and a probiotic complex reduced the 
disease severity through inhibition of immune response [145]. Total IgG, IgG1 and IgG2a 
levels were reduced in the serum of mice treated with CoQ10. Besides, the downregula-
tion of pro-inflammatory cytokines such as IL17, IL6, and IFN, and the up-regulation of 
the anti-inflammatory cytokine IL10 were observed after CoQ10 treatment. In line with 
previous studies, CoQ10 also affected the reciprocal balance of Th17/Treg, increasing Treg 
differentiation and decreasing Th17 differentiation. 
The synergic effect of CoQ10 and drugs with anti-inflammatory and antioxidant 
properties has also been demonstrated in preclinical models of RA. Jhun et al. treated 
CIA mice with metformin (Met) (1 mg/mouse), CoQ10 (0.1 mg/mouse), the combination of 
both of them, and anti-TNF therapy [146]. The combination of Met and CoQ10 resulted in 
a lower degree of cartilage damage and inflammation than Met, CoQ10 and anti-TNF 
therapy alone. The combination of Met and CoQ10 also promoted the reduction of 
pro-inflammatory cytokines such as TNF, IL6, and IL1 in the joints compared with the 
other treatments alone. Besides, the drug combination significantly reduced the levels of 
total IgG and the proportion of Th-17 cells and induced the differentiation of Foxp3 T-reg 
cells. Regarding the altered oxidative status presented in the CIA model, the combination 
of Met and CoQ10 suppressed mitochondrial dysfunction, reduced the expression of ni-
tro-tyrosine and increased mitochondrial respiration capacity. These results were also 
more prominent when Met and CoQ10 were used in combination compared with Met, 
CoQ10 and anti-TNF alone. 
Bauerova et al. demonstrated that the combination of CoQ10 with methotrexate 
(MTX), the most commonly prescribed disease-modifying anti-rheumatic drugs, sup-
pressed the progression of RA in rats more effectively than MTX alone [147]. Adjuvant 
arthritis (AA) was induced by the injection of Mycobacterium butyricum in rats. CoQ10 
was supplemented in a daily oral dose of 20 mg/kg, while MTX was administered orally 
at a dose of 0.3 mg/kg twice a week. AA rats with MTX, CoQ10 or the combination of MTX 
and CoQ10 were evaluated on days 14, 21 and 28. The combination therapy was the most 
effective in reducing the hind paw volume of arthritic animals on all selected days. These 
results were in line with the reduction of oxidative stress markers in plasma close to the 
control group such as protein carbonyls and MDA- and HNE-protein adducts by the 
combination of MTX and CoQ10 therapy. Regarding immunomodulatory effects of these 
therapies, the functionality of peripheral blood neutrophils including phagocytosis, oxi-
dative burst and metabolic activity was improved with the combination therapy, which 
also reduced the levels of IL1 in plasma. All the effects were more pronounced with the 
combination of MTX and CoQ10 than MTX or CoQ10 alone. 
Tawfik et al. validated the anti-arthritic effect of the combination of MTX and CoQ10 
in the AA model and further explored the protective role of CoQ10 in the hepatotoxicity 
induced by MTX [148]. Liver markers such as the serum levels of Alanine Aminotrans-
ferase (SGPT), Aspartate Aminotransferase (SGOT), Alkaline phosphatase (ALP), and 
total bilirubin were improved after the combined treatment of MTX with CoQ10 com-
pared with MTX alone. Furthermore, oxidative stress markers and inflammatory cyto-
kines altered by the MTX therapy in the liver were ameliorated when MTX was com-
bined with CoQ10. These results were confirmed by the histopathological evaluation of 
the liver where the combination therapy attenuated the intensity of liver injury such as 
necrosis and inflammation promoted by MTX therapy in the AA model. These results 
highlighted the dual role of CoQ10 in improving the efficacy and minimizing the adverse 
effects of MTX. 
The potential of CoQ10 as useful therapeutic tool in RA exhibited by preclinical 
studies in several mouse models of RA has also been confirmed in a randomized, double 
blind, placebo-controlled trial in patients with RA. Abdollahzad et al. conducted a clini-
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cal trial in 44 patients with moderate activity of RA who received either 100 mg/day of 
CoQ10 (n = 22) or placebo (n = 22) for two months [149]. Blood samples were collected 
before and after the intervention to evaluate changes in oxidative and inflammatory 
markers. Adverse effects were not observed during the intervention. The supplementa-
tion with CoQ10 promoted a reduction in the serum levels of malondialdehyde (MDA) 
which was not observed in the placebo group. However total antioxidant capacity in 
serum did not change between both groups of patients. Furthermore, the serum levels of 
TNF-alpha were significantly reduced in RA patients supplemented with CoQ10 com-
pared with the placebo group, while a trend towards a reduction in IL6 levels was also 
noticed. 
In line with these results, Nachvak et al. have recently conducted another clinical 
trial in 54 RA patients where the effect of CoQ10 in clinical and serological features of RA 
has been evaluated [150]. RA patients with high activity were randomly assigned into 
two groups of 27 subjects to receive either 100 mg/day of CoQ10 or placebo for two 
months. The clinical assessment of these patients after the intervention revealed that the 
supplementation with CoQ10 significantly reduced the disease activity score (DAS28) 
(from 5 to 2.34), the swollen joint count (from 2 to 0), the tender joint count (from 4.5 to 0) 
and the visual analogue scale (VAS) score. Complementary analysis including the 
erythrocyte sedimentation rate and the serum level of matrix metalloproteinase-3 
(MMP3) was also significantly reduced after the intervention. These changes were not 
observed in the placebo group. 
Altogether, these results support the beneficial effect of CoQ10 in the control of the 
oxidative and inflammatory status of RA patients which is translated in the amelioration 
of the disease activity and their clinical manifestations (Figure 3 and Table 1). Large ad-
ditional clinical trials in independent cohorts are needed to validate these results, as well 
as to evaluate its potential synergic effects with disease-modifying anti-rheumatic drugs. 
These approaches might favor the establishment of CoQ10 as a complementary therapeu-
tic tool for the future management of RA. 
3.3. Type I Diabetes 
The capacity of CoQ10 to reduce oxidative stress and inflammation and ameliorate 
other clinical features associated with T1D like neuropathic pain was revealed in a 
pre-clinical mouse model of T1D induced by streptozotocin [151]. As neural tissue is es-
pecially vulnerable to oxidative stress associated with chronic hyperglycemia, samples 
from dorsal root ganglia, sciatic nerves, and spinal cord, as well as serum, were obtained 
after the intervention with CoQ10 (150 mg/kg). Hyperglycemia induced an increase in li-
pid peroxide levels. However, mice treated with CoQ10 exhibited a reduction of lipid 
peroxide levels in serum, dorsal root ganglia and sciatic nerves which reflect its antioxi-
dant capacity. Regarding the analysis of the inflammatory status, hyperglycemic mice 
showed an increase in the levels of inflammatory mediators such as p65 (the activated 
marker of nuclear factor-κB) and CCL2. Mice treated with CoQ10 presented a reduction in 
the levels of these inflammatory mediators in dorsal root ganglia. The anti-inflammatory 
properties of CoQ10 in this tissue were also confirmed at protein and mRNA levels. These 
results were in line with the prophylactic and antinociceptive effects of CoQ10 on the di-
abetic neuropathic pain developed by this T1D mouse model. Accordingly, in an ex-
perimental model of type 2 diabetic nephropathy (db/db), which showed a deficiency in 
mitochondrial oxidized CoQ10, its supplementation preserved renal mitochondrial dys-
function by reducing both excess renal mitochondrial hydrogen peroxide production and 
mitochondrial membrane potential [152]. 
In patients with T1D, several studies have also evaluated the potential of CoQ10 
supplementation to reduce the oxidative and inflammatory status present in this disease. 
Montano et al. conducted a study in which 13 T1D patients were supplemented with 100 
mg of Ubiquinone (CoQ10) twice daily for 12 weeks [153]. The levels of CoQ10 were sig-
nificantly increased in serum of these patients after the supplementation and were di-
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rectly associated with an improvement in the redox balance and lipid profile. Thus, the 
plasma concentrations of oxidized LDL and total cholesterol were significantly reduced 
after CoQ10 supplementation, while serum levels of redox regulating protein glu-
taredoxin 1 (Grx1) activity and total antioxidant capacity were increased, leading to a less 
oxidant extracellular environment. 
Brauner et al. supplemented 23 T1D and T2D patients with 100 mg of CoQ10 twice 
daily for 12 weeks and evaluated changes in antimicrobial peptides and NK cells, both 
components of the innate immune response associated with diabetes [154]. After the 
supplementation, the levels of human beta-defensin-2 (hBD2) were strongly reduced in 
serum of T1D patients. Furthermore, CoQ10 induced changes in subset distribution and 
activation markers of NK cells, improving their activity in T1D patients. 
These results highlight the potential of CoQ10 supplementation in the control of key 
features of T1D, such as the altered immune response and redox status associated with 
the disease (Figure 3 and Table 1). However, clinical trials aiming to evaluate the role of 
CoQ10 in the control of blood glucose in patients with T1D have failed so far [155,156]. 
3.4. Multiple Sclerosis 
Supplementation with CoQ10 in a pre-clinical mouse model of multiple sclerosis 
(MS) has recently demonstrated its capacity to enhance remyelination and regulate in-
flammation. Khalilian et al. studied the demyelination-remyelination process in a 
well-stablished model of MS induced by Cuprizone (CPZ) intoxication [157]. MS mice 
were treated orally with 150 mg/kg of CoQ10 for eight weeks in combination with CPZ 
which started four weeks earlier. Control groups included MS mice treated with CPZ for 
12 weeks and healthy mice. Histological analysis of some brain regions like corpus cal-
losum (CC) evidenced the reduction of myelin levels in CPZ mice. CoQ10 supplementa-
tion reversed these effects, attenuating the destructive damage exhibited by CPZ. More-
over, genes related to remyelination such as oligodendrocyte transcription factor-1 (Ol-
ig1) and myelin basic protein (MBP) were significantly increased in the brain tissue of the 
CoQ10 group. These results were supported by changes in behavior of these mice, as de-
termined by tall suspension and open field test. Besides, CoQ10 promoted changes in the 
oxidative and inflammatory status altered in the MS model. Thus, CoQ10 promoted the 
increase of the superoxide dismutase (SOD) activity and total antioxidant capacity, and 
the reduction of pro-inflammatory cytokines such as IL6 and TNF in mice brain tissue. 
Recently, Moccia et al. performed an open-label crossover design in 60 relaps-
ing-remitting patients with MS to evaluate the effect of CoQ10 supplementation [158]. 
Thirty patients were treated with interferon beta1a alone and 30 patients were treated 
with interferon in combination with 200 mg/day of CoQ10 for three months. The oxidative 
status was markedly improved after CoQ10 supplementation including an increase in 
markers of free radical scavenging activity (uric acid and bilirubin) and a reduction of 
intracellular ROS and DNA damage (8-OHdG). The inflammatory profile was also 
modulated by CoQ10 in the serum of patients with MS. The levels of anti-inflammatory 
mediators such as IL4 and IL13 were increased, while a panel of pro-inflammatory mol-
ecules including TNF-alpha, IFN-gamma, IL-1-alpha, IL-2R, IL17F, IL-9, MIP-1α, eotaxin, 
RANTES, HGF and VEGF was reduced after three months of CoQ10 supplementation. 
Along with these molecular effects, CoQ10 also promoted changes in clinical features of 
MS evidenced by the significant reduction of Expanded Disability Status Scale (EDSS), 
Fatigue severity scale (FSS), Beck’s depression inventory (BDI) II and Visual Analogue 
Scale (VAS) for pain. 
Sanoobar et al. conducted a randomized, double-blinded, placebo-controlled trial in 
50 patients with MS to evaluate the effect of CoQ10. Several results were obtained and 
published in three different works where the beneficial effect of CoQ10 in the oxidative 
status [159], the pro-inflammatory profile [56] and clinical features [57] were highlighted. 
Patients were supplemented with 500 mg/day of CoQ10 (n = 24) or placebo (n = 24) for 12 
weeks. CoQ10 supplementation promoted a significant increase in antioxidant markers 
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such as SOD activity and total antioxidant capacity, as well as a reduction of oxidative 
markers such as malondialdehyde (MDA) levels in the serum of patients with MS [55]. 
Furthermore, the analysis of pro-inflammatory mediators in the serum of these patients 
revealed that CoQ10 ameliorated the inflammatory status of MS patients through the re-
duction of the levels of TNFα, IL-6 and MMP9 compared with the placebo group [160]. 
Finally, clinical features of patients with MS such as fatigue or depression were also im-
proved after the intervention noticed by the reduction of FSS and BDI respectively [161]. 
Overall, CoQ10 supplementation has demonstrated the potential to improve clinical 
and molecular features of patients with MS (Figure 3). However larger and long-term 
follow-up studies are needed to validate and reinforce its protective role in this disease. 
4. Conclusions 
Oxidative stress damages both molecules and cellular structures, thus altering the 
correct function of organs and systems, inducing tissue inflammation, dyslipidemia and 
atherosclerosis. In addition, oxidative stress may foster immunomodulation, which leads 
to the development of chronic autoimmune diseases. Likewise, long-term treatments 
may promote changes in systemic oxidative stress. A role for mitochondrial dysfunction 
has been further proposed in the immune dysregulation and organ damage characteristic 
of autoimmune diseases. 
In the search for potential therapeutic tools that modify mitochondrial function and 
immunometabolism in these disorders, including antiphospholipid syndrome, systemic 
lupus erythematosus, rheumatoid arthritis, diabetes mellitus or multiple sclerosis, ex-
perimental models and clinical trials have examined the safety and efficacy of CoQ10, a 
vital component of the mitochondrial respiratory chain with a crucial role in ATP pro-
duction that acts as an antioxidant with cell-protective effects, and has been demon-
strated to be helpful in numerous chronic and cardiovascular diseases. 
These studies have shown that CoQ10 supplementation to standard therapy ame-
liorates the main symptoms that characterize autoimmunity, namely inflammation, 
vascular endothelial dysfunction, and cardiovascular risk. Moreover, after CoQ10 thera-
py, along with a global decline of disease activity, each autoimmune pathology benefits 
from specific improvements to damaged organs (i.e., kidneys in SLE patients, cartilage, 
joints and synovial tissue in RA), or even to progress in neurological involvement (i.e., in 
depression in multiple sclerosis). 
Hence, CoQ10 can be considered as an important coadjuvant in the treatment of 
chronic conditions affecting the immune system. Nevertheless, few randomized trials 
analyzing the effects of CoQ10 or its derivatives in reducing disease progression and im-
proving quality of life have been developed to date in the setting of autoimmunity. Thus, 
more focused trials on larger cohorts of autoimmune disorders are needed in order to 
authenticate the promising effects of CoQ10. 
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